{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T16:28:39Z","timestamp":1764174519750,"version":"3.37.3"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2018,6,18]],"date-time":"2018-06-18T00:00:00Z","timestamp":1529280000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2018,6,18]],"date-time":"2018-06-18T00:00:00Z","timestamp":1529280000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["U01 CA167552","CA097193","CA34944","5P50 CA090381","P30 CA008748"],"award-info":[{"award-number":["U01 CA167552","CA097193","CA34944","5P50 CA090381","P30 CA008748"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["HL26490","HL34595"],"award-info":[{"award-number":["HL26490","HL34595"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000892","name":"Prostate Cancer Foundation","doi-asserted-by":"publisher","award":["Young Investigator Award"],"award-info":[{"award-number":["Young Investigator Award"]}],"id":[{"id":"10.13039\/100000892","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Causes Control"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1007\/s10552-018-1049-5","type":"journal-article","created":{"date-parts":[[2018,6,18]],"date-time":"2018-06-18T05:51:10Z","timestamp":1529301070000},"page":"775-784","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Regular aspirin use and gene expression profiles in prostate cancer patients"],"prefix":"10.1007","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0722-1311","authenticated-orcid":false,"given":"Konrad H.","family":"Stopsack","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7144-693X","authenticated-orcid":false,"given":"Ericka M.","family":"Ebot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0272-9228","authenticated-orcid":false,"given":"Mary K.","family":"Downer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9500-8907","authenticated-orcid":false,"given":"Travis A.","family":"Gerke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2637-6036","authenticated-orcid":false,"given":"Jennifer R.","family":"Rider","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7275-0597","authenticated-orcid":false,"given":"Philip W.","family":"Kantoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2551-4927","authenticated-orcid":false,"given":"Lorelei A.","family":"Mucci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,6,18]]},"reference":[{"key":"1049_CR1","doi-asserted-by":"publisher","first-page":"3540","DOI":"10.1200\/JCO.2011.41.0308","volume":"30","author":"KS Choe","year":"2012","unstructured":"Choe KS, Cowan JE, Chan JM, Carroll PR, D\u2019Amico AV, Liauw SL (2012) Aspirin use and the risk of prostate cancer mortality in men treated with prostatectomy or radiotherapy. J Clin Oncol 30:3540\u20133544","journal-title":"J Clin Oncol"},{"key":"1049_CR2","doi-asserted-by":"publisher","first-page":"635641","DOI":"10.1016\/j.eururo.2013.01.007","volume":"65","author":"HH Grytli","year":"2014","unstructured":"Grytli HH, Fagerland MW, Fossa SD, Tasken KA. (2014) Association between use of beta-blockers and prostate cancer-specific survival: a cohort study of 3561 prostate cancer patients with high-risk or metastatic disease. Eur Urol 65:635\u2013641","journal-title":"Eur Urol"},{"key":"1049_CR3","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s10552-013-0306-x","volume":"25","author":"CR Cardwell","year":"2014","unstructured":"Cardwell CR, Flahavan EM, Hughes CM et al (2014) Low-dose aspirin and survival in men with prostate cancer: a study using the UK Clinical Practice Research Datalink. Cancer Causes Control 25:33\u201343","journal-title":"Cancer Causes Control"},{"key":"1049_CR4","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1158\/1940-6207.CAPR-12-0171","volume":"5","author":"PK Dhillon","year":"2012","unstructured":"Dhillon PK, Kenfield SA, Stampfer MJ, Giovannucci EL, Chan JM (2012) Aspirin use after a prostate cancer diagnosis and cancer survival in a prospective cohort. Cancer Prev Res (Phila) 5:1223\u20131228","journal-title":"Cancer Prev Res (Phila)"},{"key":"1049_CR5","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1093\/annonc\/mdt428","volume":"25","author":"EM Flahavan","year":"2014","unstructured":"Flahavan EM, Bennett K, Sharp L, Barron TI (2014) A cohort study investigating aspirin use and survival in men with prostate cancer. Ann Oncol 25:154\u2013159","journal-title":"Ann Oncol"},{"key":"1049_CR6","doi-asserted-by":"publisher","first-page":"3716","DOI":"10.1200\/JCO.2013.54.8875","volume":"32","author":"EJ Jacobs","year":"2014","unstructured":"Jacobs EJ, Newton CC, Stevens VL, Campbell PT, Freedland SJ, Gapstur SM (2014) Daily aspirin use and prostate cancer-specific mortality in a large cohort of men with nonmetastatic prostate cancer. J Clin Oncol 32:3716\u20133722","journal-title":"J Clin Oncol"},{"key":"1049_CR7","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1016\/j.juro.2014.11.018","volume":"193","author":"J Assayag","year":"2015","unstructured":"Assayag J, Pollak MN, Azoulay L (2015) The use of aspirin and the risk of mortality in patients with prostate cancer. J Urol 193:1220\u20131225","journal-title":"J Urol"},{"key":"1049_CR8","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/j.eururo.2017.01.044","volume":"72","author":"MK Downer","year":"2017","unstructured":"Downer MK, Allard CB, Preston MA et al (2017) Regular aspirin use and the risk of lethal prostate cancer in the physicians\u2019 health study. Eur Urol 72:821\u2013827","journal-title":"Eur Urol"},{"key":"1049_CR9","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(10)62110-1","volume":"377","author":"PM Rothwell","year":"2011","unstructured":"Rothwell PM, Fowkes FG, Belch JF, Ogawa H, Warlow CP, Meade TW (2011) Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet 377:31\u201341","journal-title":"Lancet"},{"key":"1049_CR10","doi-asserted-by":"publisher","first-page":"173186","DOI":"10.1038\/nrc.2016.4","volume":"16","author":"DA Drew","year":"2016","unstructured":"Drew DA, Cao Y, Chan AT. (2016) Aspirin and colorectal cancer: the promise of precision chemoprevention. Nat Rev Cancer 16:173\u2013186","journal-title":"Nat Rev Cancer"},{"key":"1049_CR11","doi-asserted-by":"publisher","first-page":"6167","DOI":"10.1038\/bjc.2014.271","volume":"111","author":"L Alfonso","year":"2014","unstructured":"Alfonso L, Ai G, Spitale RC, Bhat GJ. (2014) Molecular targets of aspirin and cancer prevention. Br J Cancer. 111:61\u201367","journal-title":"Br J Cancer"},{"key":"1049_CR12","doi-asserted-by":"publisher","first-page":"5292","DOI":"10.1073\/pnas.96.9.5292","volume":"96","author":"XM Xu","year":"1999","unstructured":"Xu XM, Sansores-Garcia L, Chen XM, Matijevic-Aleksic N, Du M, Wu KK (1999) Suppression of inducible cyclooxygenase 2 gene transcription by aspirin and sodium salicylate. Proc Natl Acad Sci USA 96:5292\u20135297","journal-title":"Proc Natl Acad Sci USA"},{"key":"1049_CR13","doi-asserted-by":"publisher","first-page":"2485","DOI":"10.1002\/cncr.21075","volume":"103","author":"GM Sclabas","year":"2005","unstructured":"Sclabas GM, Uwagawa T, Schmidt C et al (2005) Nuclear factor kappa B activation is a potential target for preventing pancreatic carcinoma by aspirin. Cancer 103:2485\u20132490","journal-title":"Cancer"},{"key":"1049_CR14","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1126\/science.1132939","volume":"313","author":"J Lamb","year":"2006","unstructured":"Lamb J, Crawford ED, Peck D et al (2006) The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science 313:1929\u20131935","journal-title":"Science"},{"key":"1049_CR15","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/nm.4306","volume":"23","author":"SM Corsello","year":"2017","unstructured":"Corsello SM, Bittker JA, Liu Z et al (2017) The drug repurposing hub: a next-generation drug library and information resource. Nat Med 23:405\u2013408","journal-title":"Nat Med"},{"key":"1049_CR16","first-page":"129135","volume":"321","author":"Steering Committee of the Physicians","year":"1989","unstructured":"Steering Committee of the Physicians\u2019 Health Study Research Group (1989) Final report on the aspirin component of the ongoing Physicians\u2019 Health Study. N Engl J Med 321:129\u2013135","journal-title":"N Engl J Med"},{"key":"1049_CR17","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1002\/ijc.22788","volume":"121","author":"E Giovannucci","year":"2007","unstructured":"Giovannucci E, Liu Y, Platz EA, Stampfer MJ, Willett WC (2007) Risk factors for prostate cancer incidence and progression in the health professionals follow-up study. Int J Cancer 121:1571\u20131578","journal-title":"Int J Cancer"},{"key":"1049_CR18","doi-asserted-by":"publisher","first-page":"8187","DOI":"10.1158\/1078-0432.CCR-16-1245","volume":"23","author":"JA Sinnott","year":"2017","unstructured":"Sinnott JA, Peisch SF, Tyekucheva S et al. (2017) Prognostic utility of a new mRNA expression signature of Gleason score. Clin Cancer Res 23:81\u201387","journal-title":"Clin Cancer Res"},{"key":"1049_CR19","doi-asserted-by":"publisher","first-page":"719726","DOI":"10.1158\/1055-9965.EPI-16-0237","volume":"26","author":"P Zareba","year":"2017","unstructured":"Zareba P, Flavin R, Isikbay M et al. (2017) Perineural invasion and risk of lethal prostate cancer. Cancer Epidemiol Biomark Prev 26:719\u2013726","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"1049_CR20","doi-asserted-by":"publisher","first-page":"255260","DOI":"10.1158\/1055-9965.EPI-14-0694-T","volume":"24","author":"KL Penney","year":"2015","unstructured":"Penney KL, Sinnott JA, Tyekucheva S et al. (2015) Association of prostate cancer risk variants with gene expression in normal and tumor tissue. Cancer Epidemiol Biomark Prev 24:255\u2013260","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"1049_CR21","doi-asserted-by":"publisher","first-page":"3069","DOI":"10.1093\/bioinformatics\/btv313","volume":"31","author":"M Yoo","year":"2015","unstructured":"Yoo M, Shin J, Kim J et al (2015) DSigDB: drug signatures database for gene set analysis. Bioinformatics 31:3069\u20133071","journal-title":"Bioinformatics"},{"key":"1049_CR22","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian A, Tamayo P, Mootha VK et al (2005) Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 102:15545\u201315550","journal-title":"Proc Natl Acad Sci USA"},{"key":"1049_CR23","doi-asserted-by":"publisher","first-page":"4130","DOI":"10.1002\/cncr.30831","volume":"123","author":"EM Ebot","year":"2017","unstructured":"Ebot EM, Gerke T, Labbe DP et al (2017) Gene expression profiling of prostate tissue identifies chromatin regulation as a potential link between obesity and lethal prostate cancer. Cancer 123:4130\u20134138","journal-title":"Cancer"},{"key":"1049_CR24","doi-asserted-by":"publisher","first-page":"D1049-56","DOI":"10.1093\/nar\/gku1179","volume":"43","author":"Gene Ontology Consortium","year":"2015","unstructured":"Gene Ontology Consortium (2015) Gene Ontology Consortium: going forward. Nucleic Acids Res 43: D1049-56","journal-title":"Nucleic Acids Res"},{"key":"1049_CR25","doi-asserted-by":"publisher","first-page":"e13984","DOI":"10.1371\/journal.pone.0013984","volume":"5","author":"D Merico","year":"2010","unstructured":"Merico D, Isserlin R, Stueker O, Emili A, Bader GD (2010) Enrichment map: a network-based method for gene-set enrichment visualization and interpretation. PLoS ONE 5:e13984","journal-title":"PLoS ONE"},{"key":"1049_CR26","doi-asserted-by":"publisher","first-page":"172180","DOI":"10.1002\/(SICI)1097-0045(20000215)42:3<172::AID-PROS2>3.0.CO;2-R","volume":"42","author":"R Rotem","year":"2000","unstructured":"Rotem R, Tzivony Y, Flescher E (2000) Contrasting effects of aspirin on prostate cancer cells: suppression of proliferation and induction of drug resistance. Prostate 42:172\u2013180","journal-title":"Prostate"},{"key":"1049_CR27","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ejphar.2008.10.053","volume":"602","author":"W Lu","year":"2009","unstructured":"Lu W, Tinsley HN, Keeton A, Qu Z, Piazza GA, Li Y (2009) Suppression of Wnt\/beta-catenin signaling inhibits prostate cancer cell proliferation. Eur J Pharmacol 602:8\u201314","journal-title":"Eur J Pharmacol"},{"key":"1049_CR28","doi-asserted-by":"publisher","first-page":"41047","DOI":"10.1074\/jbc.M503713200","volume":"280","author":"KM Kim","year":"2005","unstructured":"Kim KM, Song JJ, An JY, Kwon YT, Lee YJ (2005) Pretreatment of acetylsalicylic acid promotes tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by down-regulating BCL-2 gene expression. J Biol Chem 280:41047\u201341056","journal-title":"J Biol Chem"},{"key":"1049_CR29","doi-asserted-by":"publisher","first-page":"7727","DOI":"10.1158\/1078-0432.CCR-04-0732","volume":"10","author":"BA Narayanan","year":"2004","unstructured":"Narayanan BA, Narayanan NK, Pittman B, Reddy BS (2004) Regression of mouse prostatic intraepithelial neoplasia by nonsteroidal anti-inflammatory drugs in the transgenic adenocarcinoma mouse prostate model. Clin Cancer Res 10:7727\u20137737","journal-title":"Clin Cancer Res"},{"key":"1049_CR30","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1124\/mol.107.039610","volume":"72","author":"J Yoo","year":"2007","unstructured":"Yoo J, Lee YJ (2007) Aspirin enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in hormone-refractory prostate cancer cells through survivin down-regulation. Mol Pharmacol 72:1586\u20131592","journal-title":"Mol Pharmacol"},{"key":"1049_CR31","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1159\/000464434","volume":"41","author":"C Shi","year":"2017","unstructured":"Shi C, Zhang N, Feng Y, Cao J, Chen X, Liu B (2017) Aspirin inhibits IKK-beta-mediated prostate cancer cell invasion by targeting matrix metalloproteinase-9 and urokinase-type plasminogen activator. Cell Physiol Biochem 41:1313\u20131324","journal-title":"Cell Physiol Biochem"},{"key":"1049_CR32","first-page":"1277","volume":"23","author":"FP Lloyd Jr","year":"2003","unstructured":"Lloyd FP Jr, Slivova V, Valachovicova T, Sliva D (2003) Aspirin inhibits highly invasive prostate cancer cells. Int J Oncol 23:1277\u20131283","journal-title":"Int J Oncol"},{"key":"1049_CR33","doi-asserted-by":"publisher","first-page":"431441","DOI":"10.1530\/ERC-12-0344","volume":"20","author":"E Kashiwagi","year":"2013","unstructured":"Kashiwagi E, Shiota M, Yokomizo A et al. (2013) Prostaglandin receptor EP3 mediates growth inhibitory effect of aspirin through androgen receptor and contributes to castration resistance in prostate cancer cells. Endocr Relat Cancer 20:431\u2013441","journal-title":"Endocr Relat Cancer"},{"key":"1049_CR34","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1093\/jnci\/djt331","volume":"105","author":"H Nan","year":"2013","unstructured":"Nan H, Morikawa T, Suuriniemi M et al (2013) Aspirin use, 8q24 single nucleotide polymorphism rs6983267, and colorectal cancer according to CTNNB1 alterations. J Natl Cancer Inst 105:1852\u20131861","journal-title":"J Natl Cancer Inst"},{"key":"1049_CR35","doi-asserted-by":"publisher","first-page":"826835","DOI":"10.7326\/M15-2112","volume":"164","author":"EP Whitlock","year":"2016","unstructured":"Whitlock EP, Burda BU, Williams SB, Guirguis-Blake JM, Evans CV. (2016) Bleeding risks with aspirin use for primary prevention in adults: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 164:826\u2013835","journal-title":"Ann Intern Med"},{"key":"1049_CR36","doi-asserted-by":"publisher","first-page":"875882","DOI":"10.1007\/s00345-016-1912-5","volume":"35","author":"KH Stopsack","year":"2017","unstructured":"Stopsack KH, Greenberg AJ, Mucci LA. (2017) Common medications and prostate cancer mortality: a review. World J Urol 35:875\u2013882","journal-title":"World J Urol"},{"key":"1049_CR37","doi-asserted-by":"publisher","first-page":"549558","DOI":"10.1016\/S1470-2045(12)70088-8","volume":"13","author":"ND James","year":"2012","unstructured":"James ND, Sydes MR, Mason MD et al. (2012) Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial. Lancet Oncol 13:549\u2013558","journal-title":"Lancet Oncol"},{"key":"1049_CR38","first-page":"8587","volume":"66","author":"CJ Watson","year":"1990","unstructured":"Watson CJ, Deane AM, Doyle PT, Bullock KN (1990) Identifiable factors in post-prostatectomy haemorrhage: the role of aspirin. Br J Urol 66:85\u201387","journal-title":"Br J Urol"},{"key":"1049_CR39","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1001\/jama.1981.03310430017013","volume":"245","author":"PC Amrein","year":"1981","unstructured":"Amrein PC, Ellman L, Harris WH (1981) Aspirin-induced prolongation of bleeding time and perioperative blood loss. JAMA 245:1825\u20131828","journal-title":"JAMA"},{"key":"1049_CR40","doi-asserted-by":"publisher","first-page":"14568","DOI":"10.1021\/ja408322b","volume":"135","author":"LA Bateman","year":"2013","unstructured":"Bateman LA, Zaro BW, Miller SM, Pratt MR (2013) An alkyne-aspirin chemical reporter for the detection of aspirin-dependent protein modification in living cells. J Am Chem Soc 135:14568\u201314573","journal-title":"J Am Chem Soc"}],"container-title":["Cancer Causes &amp; Control"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10552-018-1049-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10552-018-1049-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10552-018-1049-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,16]],"date-time":"2020-05-16T20:23:10Z","timestamp":1589660590000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10552-018-1049-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,18]]},"references-count":40,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["1049"],"URL":"https:\/\/doi.org\/10.1007\/s10552-018-1049-5","relation":{},"ISSN":["0957-5243","1573-7225"],"issn-type":[{"type":"print","value":"0957-5243"},{"type":"electronic","value":"1573-7225"}],"subject":[],"published":{"date-parts":[[2018,6,18]]},"assertion":[{"value":"16 April 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}